The Latest

NOW AVAILABLE: For the U.S. Multiple Sclerosis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

The Multiple Sclerosis market exhibited growth over 2017, with a 16% increase in materials noted in comparison with 2016, due in part to the first branded pieces received from Genentech’s Ocrevus after its approval. Growth in this area is likely to continue, as Celgene made progress towards the entry of Ozanimod over the year as well. For the fourth year in a row, Biogen’s Tecfidera surpassed the other brands in terms of the promotional volume received over the course of 2017; however, newcomers Ocrevus and Zinbryta were close behind. Multiple brands premiered new campaigns and featured comparisons with their competitors through efficacy, utilization, and formulary coverage. Biosimilars were also a hot topic, as Sandoz made multiple comparisons between Glatopa and Copaxone 20 mg/mL, while Teva emphasized the experience of Copaxone and reminded HCPs to sign the Dispense as Written line. Patients and healthcare professionals were targeted relatively evenly, with support being a priority with live and online patient events, treatment and disease education, and additional services through various programs, including savings offers.  A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the 2017 reports.

2017-MS

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Lymphoma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

The Lymphoma market expanded greatly in 2017 due to the approval of new products, including Bayer’s Aliqopa, Calquence from AstraZeneca and Acerta Pharma, Rituxan Hycela from Genentech and Biogen, and Kite Pharma’s Yescarta. Additional lymphoma indications were also added to existing brands, such as Genentech’s Gazyva, Imbruvica from Janssen and Pharmacyclics, and Merck’s Keytruda. Introductory campaigns were premiered for many of the new products, while established brands remained more consistent in their promotional imagery. Healthcare professionals were the primary targets for promotions during this time, which tended to focus on clinical data, convenient dosing, and support. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the 2017 reports.

2017-Lymphoma

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Hemophilia Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

Eloctate produced the largest share of the materials received from a single brand in the hemophilia market over 2017 as it promoted its third anniversary, new vial strengths, and the spin-off of Bioverativ from Biogen. CSL Behring announced that the manufacturing of Helixate FS would end in December 2017 and encouraged physicians to switch their patients to Afstyla, while Bayer took the opportunity to urge patients to consider Kovaltry as a replacement. The market grew as the first branded piece for Hemlibra was received from Genentech, promoting the product’s approval, and Novo Nordisk announced that Rebinyn would be available in 2018. After an extended promotional absence, the first materials received from Ixinity featured the new “Just B” campaign and launched the Ixinity Family Room Facebook page. A satisfaction guarantee for Novoeight was offered, and it was stated that “more patients have switched to Novoeight than to any standard half-life rFVIII since launch.” Shire stressed its commitment to the bleeding disorders community through multiple unbranded and co-branded materials. Multiple new campaigns were premiered, and priority messages continued to consist of those regarding product convenience and patient support. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the 2017 reports.

2017-Hemophilia

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Melanoma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q4 2017.

Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo/Yervoy dominated the melanoma market during this time period, each producing 37% of the promotional volume received. Keytruda presented its new “Key” campaign theme, alongside an efficacy message, and emphasized support resources. Novartis Oncology’s Mekinist/Tafinlar provided patients with a treatment guide and positioned the combination therapy for patients with a certain type of BRAF+ advanced melanoma. Opdivo/Yervoy highlighted its experience within multiple cancer markets, offered support resources, and announced a new FDA approval inside the melanoma market. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.Q4-2017-Melanoma

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Neuroendocrine and Carcinoid Tumors Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q4 2017.

The largest proportion of material in the neuroendocrine and carcinoid tumors market was received from Novartis’s Sandostatin LAR Depot, comprising 26%. Sandostatin LAR Depot’s “Control You Can Trust” campaign emphasized system control with multiple dosing options. Novartis’s Afinitor presented its “Press Pause On Progression” campaign, which encouraged healthcare professionals to prescribe Afinitor at the first sign of NET progression. Ipsen’s Somatuline Depot displayed its “3 Reasons” campaign, which highlighted efficacy, the new carcinoid syndrome, and delivery. Multiple brands emphasized clinical trial results and patient support. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Q4-2017-Neuroendocrine-and-

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

NOW AVAILABLE: For the Multiple Myeloma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q4 2017.

Onyx Pharmaceuticals’s Kyprolis was the multiple myeloma market leader in terms of promotional volume received, capturing 34%. Kyprolis displayed two campaigns, which included the recurring “Respond” campaign and the new “Live Longer” DTC campaign, emphasizing superior progression-free survival, complete response rates, and new overall survival data. Janssen Biotech’s Darzalex presented the “Discover” campaign to patients, which promoted Darzalex as a treatment options for relapsed multiple myeloma patients. Takeda Oncology’s Ninlaro continued to display the “Extend” campaign to highlight efficacy. Celgene offered Pomalyst and Revlimid patients Myeloma Central and the Celgene Patient Support program. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Q4-2017-MM

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

NOW AVAILABLE: For the Immune Thrombocytopenic Purpura (ITP) Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

Novartis’s Promacta dominated the ITP market during this time period, producing 71% of the promotional volume received.  Efforts for Promacta focused on the “Platelet” campaign, which highlighted efficacy and safety in clinical trials, as well as dosing and mechanism of action.  Access through the Universal Co-Pay Card and PANO was also promoted throughout the year.  Meanwhile, Amgen’s Nplate used the “Stability” campaign to demonstrate its safety and efficacy in studies, as well as its once-weekly dosing.  Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

2017-ITP-Graph

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the U.S. Biologics for Rheumatoid Arthritis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

Pfizer’s Xeljanz franchise was the clear promotional leader within the RA market throughout the year, responsible for 21% of the 360 pieces received, making this the fifth year in a row that this franchise captured the top spot. The market continued to expand during this time, with the approval of Boehringer Ingelheim’s Cyltezo, Merck’s announcement of the availability of Renflexis, and the introduction of Kevzara by Sanofi Genzyme and Regeneron. New campaigns were premiered by multiple brands throughout the year, and new educational and support programs were also launched. The entry of biosimilars continued to be a hot topic as Pfizer worked to educate healthcare professionals on Inflectra’s similarity to the reference product and potential cost savings. Janssen’s Remicade focused on setting itself apart from biosimilars by presenting information on the FDA interchangeability designation, along with the new Finely Tuned patient video series, which featured patients talking about why they want to stay on Remicade. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the 2017 reports.

2017-RA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. HIV Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

Gilead dominated the HIV market for the majority of the year; however, ViiV Healthcare captured the top spot from Gilead in Q3 in terms of promotional volume received. When analyzing volume by brand, ViiV’s Triumeq slightly edged out Gilead’s Genvoya, producing 61 versus 59 of the pieces received, respectively. New products were introduced during this time, as Merck announced the approval of Isentress HD, ViiV introduced Juluca, and Selzentry highlighted a new oral solution and approval for pediatric patients. Unbranded marketing was common from both Gilead and ViiV, typically promoting HIV prevention and education, while multiple products presented new campaigns as well. Messaging across brands consistently promoted various savings and support programs, including an announcement from Bristol-Myers Squibb and Gilead regarding the transfer of access support for Atripla from BMS3assist to Gilead Advancing Access as of January 1, 2018. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the 2017 reports.

2017-HIV

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. COPD Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2017.

GSK produced the highest proportion of materials received in terms of corporate volume for their Ellipta portfolio over the majority of the year; however, AstraZeneca was the leader in terms of promotional volume during Q1. In terms of individual brands, GSK again took the lead with 18% of the yearly promotions received in support of Breo Ellipta, followed closely by relative newcomer, Bevespi Aerosphere from AstraZeneca. Competition in this market increased as Sunovion distributed the first branded materials for their trio of new products, Utibron Neohaler, Seebri Neohaler, and Lonhala Magnair, while GSK publicized Trelegy Ellipta’s approval. The majority of products focused on patient access through the heavy distribution of formulary information, and comparisons across brands in the areas of efficacy, cost, and coverage were commonly utilized promotional strategies. Convenient dosing and efficacy supported by clinical trial data were commonly highlighted messages as well. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the 2017 reports.

2017-COPD

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com